PA8795701A1 - Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3 - Google Patents
Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3Info
- Publication number
- PA8795701A1 PA8795701A1 PA20088795701A PA8795701A PA8795701A1 PA 8795701 A1 PA8795701 A1 PA 8795701A1 PA 20088795701 A PA20088795701 A PA 20088795701A PA 8795701 A PA8795701 A PA 8795701A PA 8795701 A1 PA8795701 A1 PA 8795701A1
- Authority
- PA
- Panama
- Prior art keywords
- histamine
- isoquinolinilo
- isoindolinilo
- antagonists
- derivatives
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960001340 histamine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99363607P | 2007-09-12 | 2007-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8795701A1 true PA8795701A1 (es) | 2009-04-23 |
Family
ID=40261509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20088795701A PA8795701A1 (es) | 2007-09-12 | 2008-09-12 | Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20090069300A1 (enExample) |
| EP (1) | EP2200989A1 (enExample) |
| JP (1) | JP2010539180A (enExample) |
| KR (1) | KR20100054856A (enExample) |
| CN (1) | CN101848896A (enExample) |
| AP (1) | AP2010005202A0 (enExample) |
| AR (1) | AR068423A1 (enExample) |
| AU (1) | AU2008298926A1 (enExample) |
| BR (1) | BRPI0817061A2 (enExample) |
| CA (1) | CA2699384A1 (enExample) |
| CL (1) | CL2008002726A1 (enExample) |
| CO (1) | CO6300955A2 (enExample) |
| CR (1) | CR11303A (enExample) |
| DO (1) | DOP2010000079A (enExample) |
| EA (1) | EA201000316A1 (enExample) |
| EC (1) | ECSP10010025A (enExample) |
| MA (1) | MA31699B1 (enExample) |
| MX (1) | MX2010002760A (enExample) |
| NI (1) | NI201000036A (enExample) |
| PA (1) | PA8795701A1 (enExample) |
| PE (1) | PE20090651A1 (enExample) |
| TN (1) | TN2010000105A1 (enExample) |
| TW (1) | TW200927114A (enExample) |
| WO (1) | WO2009036144A1 (enExample) |
| ZA (1) | ZA201001751B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200823204A (en) * | 2006-10-17 | 2008-06-01 | Arena Pharm Inc | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto |
| GB0907284D0 (en) | 2009-04-28 | 2009-06-10 | Queen Mary & Westfield College | Compounds for inducing cellular apoptosis |
| HUE034911T2 (hu) | 2009-07-27 | 2018-03-28 | Gilead Sciences Inc | Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok |
| EP2588197B1 (en) | 2010-07-02 | 2014-11-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| US20130203756A1 (en) * | 2010-10-29 | 2013-08-08 | Jamie L. Bunda | Isoindoline pde10 inhibitors |
| WO2012154760A1 (en) * | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| BR112014000267A2 (pt) | 2011-07-04 | 2016-09-20 | Bayer Ip Gmbh | utilização de isoquinolinonas, isoquinolinedionas, isoquinolinetrionas e dihidroisoquinolinonas substituídas ou, em cada caso, sais das mesmas como agentes ativos contra o stress abiótico em plantas |
| WO2013076590A1 (en) | 2011-11-23 | 2013-05-30 | Oxygen Healthcare Research Pvt. Ltd | Benzothiazine compounds as h3 receptor ligands |
| CN105254554B (zh) * | 2014-07-14 | 2018-01-30 | 南开大学 | 一种制备异吲哚啉酮类化合物的方法 |
| CA3174353A1 (en) * | 2020-04-08 | 2021-10-14 | Dominic Reynolds | Compounds and methods for modulating splicing |
| CA3191279A1 (en) * | 2020-08-28 | 2022-03-03 | Yi Liu | Heterocyclic compounds and uses thereof |
| US12496297B1 (en) * | 2020-10-23 | 2025-12-16 | Washington University | Compositions of autophagy modulating agents and uses thereof |
| CN115819347B (zh) * | 2022-11-14 | 2024-08-30 | 暨明医药科技（苏州）有限公司 | 一种1-烷基-3-溴吡唑的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3933829A (en) * | 1974-08-22 | 1976-01-20 | John Wyeth & Brother Limited | 4-Aminoquinoline derivatives |
| US4166853A (en) * | 1978-05-05 | 1979-09-04 | The Upjohn Company | Antihypertensive 7-trifluoromethyl-4-aminoquinolones |
| US4159331A (en) * | 1978-05-05 | 1979-06-26 | The Upjohn Company | Antihypertensive 4-aminoquinolines |
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| ATE253359T1 (de) * | 1997-05-01 | 2003-11-15 | Lilly Co Eli | Antithrombotische mittel |
| JP2004532834A (ja) | 2001-03-23 | 2004-10-28 | イーライ・リリー・アンド・カンパニー | ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用 |
| PT2208727E (pt) * | 2002-09-19 | 2012-10-11 | Lilly Co Eli | Éteres diarílicos como antagonista do receptor opióide |
| KR101792651B1 (ko) * | 2004-05-14 | 2017-11-20 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물 |
| US20060014733A1 (en) * | 2004-07-19 | 2006-01-19 | Pfizer Inc | Histamine-3 agonists and antagonists |
| US7381732B2 (en) * | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
| EP1848696A1 (en) * | 2005-01-21 | 2007-10-31 | Schering Corporation | Imidazole and benzimidazole derivates useful as histamine h3 antagonists |
| US20070032475A1 (en) * | 2005-04-15 | 2007-02-08 | Ye Xiaocong M | Novel compounds useful for bradykinin B1 receptor antagonism |
-
2008
- 2008-09-11 US US12/208,794 patent/US20090069300A1/en not_active Abandoned
- 2008-09-11 KR KR1020107007943A patent/KR20100054856A/ko not_active Ceased
- 2008-09-11 MX MX2010002760A patent/MX2010002760A/es not_active Application Discontinuation
- 2008-09-11 WO PCT/US2008/075981 patent/WO2009036144A1/en not_active Ceased
- 2008-09-11 EP EP08799453A patent/EP2200989A1/en not_active Withdrawn
- 2008-09-11 JP JP2010524978A patent/JP2010539180A/ja not_active Withdrawn
- 2008-09-11 AU AU2008298926A patent/AU2008298926A1/en not_active Abandoned
- 2008-09-11 CN CN200880106892A patent/CN101848896A/zh active Pending
- 2008-09-11 CA CA2699384A patent/CA2699384A1/en not_active Abandoned
- 2008-09-11 AP AP2010005202A patent/AP2010005202A0/xx unknown
- 2008-09-11 BR BRPI0817061 patent/BRPI0817061A2/pt not_active Application Discontinuation
- 2008-09-11 EA EA201000316A patent/EA201000316A1/ru unknown
- 2008-09-12 TW TW097135281A patent/TW200927114A/zh unknown
- 2008-09-12 AR ARP080103964A patent/AR068423A1/es not_active Application Discontinuation
- 2008-09-12 PE PE2008001597A patent/PE20090651A1/es not_active Application Discontinuation
- 2008-09-12 PA PA20088795701A patent/PA8795701A1/es unknown
- 2008-09-12 CL CL200802726A patent/CL2008002726A1/es unknown
-
2010
- 2010-03-04 CR CR11303A patent/CR11303A/es not_active Application Discontinuation
- 2010-03-05 TN TNP2010000105A patent/TN2010000105A1/fr unknown
- 2010-03-10 EC EC2010010025A patent/ECSP10010025A/es unknown
- 2010-03-11 NI NI201000036A patent/NI201000036A/es unknown
- 2010-03-11 DO DO2010000079A patent/DOP2010000079A/es unknown
- 2010-03-11 ZA ZA2010/01751A patent/ZA201001751B/en unknown
- 2010-03-12 MA MA32688A patent/MA31699B1/fr unknown
- 2010-03-15 CO CO10030398A patent/CO6300955A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0817061A2 (pt) | 2015-03-24 |
| WO2009036144A1 (en) | 2009-03-19 |
| AR068423A1 (es) | 2009-11-18 |
| AP2010005202A0 (en) | 2010-04-30 |
| JP2010539180A (ja) | 2010-12-16 |
| EP2200989A1 (en) | 2010-06-30 |
| AU2008298926A1 (en) | 2009-03-19 |
| DOP2010000079A (es) | 2010-03-31 |
| ECSP10010025A (es) | 2010-08-31 |
| US20090069300A1 (en) | 2009-03-12 |
| TN2010000105A1 (fr) | 2011-09-26 |
| ZA201001751B (en) | 2010-11-24 |
| MX2010002760A (es) | 2010-04-01 |
| MA31699B1 (fr) | 2010-09-01 |
| PE20090651A1 (es) | 2009-05-28 |
| TW200927114A (en) | 2009-07-01 |
| CO6300955A2 (es) | 2011-07-21 |
| CN101848896A (zh) | 2010-09-29 |
| EA201000316A1 (ru) | 2010-10-29 |
| KR20100054856A (ko) | 2010-05-25 |
| NI201000036A (es) | 2010-08-13 |
| CA2699384A1 (en) | 2009-03-19 |
| CL2008002726A1 (es) | 2008-10-10 |
| CR11303A (es) | 2010-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8795601A1 (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3 | |
| ECSP10010025A (es) | Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3 | |
| ECSP055535A (es) | Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6 | |
| CL2007001670A1 (es) | Uso de compuestos derivados de amina para el tratamiento de un trastorno mediado por citoquinas. | |
| PA8790101A1 (es) | Derivados de aminoalquilazol como antagonistas de histamina-3 | |
| CL2008001705A1 (es) | Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3. | |
| TW200800958A (en) | N-substituted-azacyclylamines as histamine-3 antagonists | |
| CR10309A (es) | "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1" | |
| ECSP055536A (es) | Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6 | |
| CO6361994A2 (es) | Antagonistas del receptor de orexina de isonicotinamida | |
| CU20100159A7 (es) | Compuestos | |
| BRPI0907382B8 (pt) | antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende | |
| WO2007136668A3 (en) | N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | |
| MX2009003645A (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3. | |
| CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
| NI201100162A (es) | Derivados de indol como antagonistas del receptor crth2 | |
| CL2016001348A1 (es) | Forma cristalina de clorhidrato de (s)-(2-(6-cloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona; composición farmacéutica que la comprende; y su uso para el tratamiento o prevención de trastornos del sueño, tales como disomnias, parasomnias, entre otras. | |
| PA8781601A1 (es) | " derivados de azaciclilbenzamida como antagonistas de histamina-3 | |
| CL2008002767A1 (es) | Compuestos derivados de heterociclico triciclico; composicion farmaceutica; y su uso para el tratamiento de un trastorno mediado por serotonina tal como obesidad, esquizofrenia y disfuncion cognitiva. | |
| CL2016000325A1 (es) | Antagonistas de vía para tratar trastornos del sueño por cambio de fase | |
| ECSP088176A (es) | Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6 | |
| CR9734A (es) | Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6 | |
| PA8814801A1 (es) | Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos | |
| UY31646A1 (es) | Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico | |
| ECSP088930A (es) | Derivados de benzoxazol y benzotiazol como ligandos de |